| P/E (FY) | — | Sales (TTM) | $0 |
| Earnings (TTM) | -$10.9M | ROE | −238.17% |
| Net Margin | — | ROIC | — |
| Debt / Equity | — | TD / EBITDA | — |
| EPS Growth 3Y | — | Sales Growth 3Y | — |
| Market Cap | $2.5M | Trading Days | 813 |
| 52W High | 79.72 |
| 52W Low | 1.39 |
| % Off High | −98.21% |
| YTD | −79.16% | 1Y | −97.59% |
| 3Y | −100.00% | Since incept. (ann.) | −97.81% |
| Ann. Volatility (1Y) | 126.04% | Ann. Volatility (3Y) | 150.57% |
| Sharpe (1Y) | −2.26 | Sharpe (3Y) | −1.84 |
| Max Drawdown (1Y) | −97.77% | Max Drawdown (3Y) | −100.00% |
| Beta (3Y, vs SPY) | −0.61 |
| Ticker | Name | Mkt cap | P/E |
|---|---|---|---|
| PKTX | ProtoKinetix, Inc. | $2.6M | — |
| OGEN | ORAGENICS INC | $2.2M | — |
| VCNX | VACCINEX, INC. | $2.2M | — |
| NXTS | Nexentis Technologies Inc. | $2.2M | — |
| DCOY | Decoy Therapeutics Inc. | $2.1M | — |
| AZTR | Azitra, Inc. | $2.1M | — |
| ARTL | ARTELO BIOSCIENCES, INC. | $2.1M | — |
| BPTH | BIO-PATH HOLDINGS, INC. | $2.0M | — |
| MTNB | Matinas BioPharma Holdings, Inc. | $1.9M | — |
| ACUT | Accustem Sciences Inc. | $3.5M | — |
| ENSC | Ensysce Biosciences, Inc. | $3.7M |
| JUNS | JUPITER NEUROSCIENCES, INC. | $4.0M | — |
